Osilodrostat: A Novel Steroidogenesis Inhibitor to Treat Cushing's Disease.

John A DoughertyDivya Sanjaykumar DesaiJavier Barrios Herrera

Published in: The Annals of pharmacotherapy (2020)

Osilodrostat was efficacious in decreasing cortisol levels and safe in treating patients who have failed or are ineligible for pituitary surgery. Although risks exist, a pivotal clinical trial revealed efficacy in 86% of participants.

Keyphrases

clinical trial
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
minimally invasive
prognostic factors
coronary artery bypass
open label
coronary artery disease
acute coronary syndrome
double blind
phase iii
atrial fibrillation
patient reported